The binding risk is still regulatory permissioning, with manufacturing readiness second. Archer can likely survive long enough to keep trying, but the equity only works well if certification, safe early operations, and a repeatable factory ramp arrive close enough together for recurring economics to emerge before
dilution or credibility fatigue sets in.